It saw a big 2023 gain!

Article Excerpt

ELI LILLY & CO., $628.91, is still a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares o/s: 949.3 million; Market cap: $602.4 billion; Dividend yield: 0.8%) was a #1 Power Buy for 2023 at $352.01 a share. It’s now up a very solid 78.7%. That gain came partly from new product launches—including a major new use for its Mounjaro drug. Lilly’s Mounjaro drug for type 2 diabetes launched in May 2022. And now, the FDA has approved Mounjaro as a weight-loss treatment. That new drug, branded as Zepbound, offers the same effects as rival drugs like Ozempic and Wegovy—but could prove even more effective, and with fewer side effects. All in all, obesity remains a major U.S. health concern, and Zepbound promises to be a huge blockbuster drug for Lilly. Eli Lilly is a buy. buy…